AC   CVCL_7966
DR   Cosmic; 1136965
DR   Cosmic; 1556194
DR   Wikidata; Q54899635
RX   PubMed=18097577;
RX   PubMed=21362583;
RX   PubMed=21631644;
RX   PubMed=26780976;
RX   PubMed=26781072;
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26780976; PubMed=26781072). Originally thought to originate from a lung metastasis of a tongue squamous cell carcinoma.
CC   Population: African American.
CC   Doubling time: 12.59 hours (PubMed=21362583).
CC   HLA typing: A*68:02 (Direct_author_submission).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
RX   PubMed=18097577; DOI=10.3892/or.19.1.65;
RA   Taguchi T., Tsukuda M., Imagawa-Ishiguro Y., Kato Y., Sano D.;
RT   "Involvement of EGFR in the response of squamous cell carcinoma of the
RT   head and neck cell lines to gefitinib.";
RL   Oncol. Rep. 19:65-71(2008).
RX   PubMed=21362583; DOI=10.1016/j.anl.2011.01.018;
RA   Sakakibara A., Tsukuda M., Kondo N., Ishiguro Y., Kimura M.,
RA   Fujita K., Takahashi H., Matsuda H.;
RT   "Examination of the optimal condition on the in vitro sensitivity to
RT   telomelysin in head and neck cancer cell lines.";
RL   Auris Nasus Larynx 38:589-599(2011).
RX   PubMed=21631644; DOI=10.1111/j.1349-7006.2011.01999.x;
RA   Kondo N., Tsukuda M., Taguchi T., Nakazaki K., Sakakibara A.,
RA   Takahashi H., Toth G., Nishimura G.;
RT   "Gene status of head and neck squamous cell carcinoma cell lines and
RT   cetuximab-mediated biological activities.";
RL   Cancer Sci. 102:1717-1723(2011).
RX   PubMed=26780976; DOI=10.3892/or.2016.4573;
RA   Sano D., Matsuda H., Ishiguro Y., Nishimura G., Kawakami M.,
RA   Tsukuda M.;
RT   "Corrigendum: Antitumor effects of IDN5109 on head and neck squamous
RT   cell carcinoma.";
RL   Oncol. Rep. 35:2494-2494(2016).
RX   PubMed=26781072; DOI=10.3892/or.2016.4574;
RA   Sano D., Kawakami M., Fujita K., Kimura M., Yamashita Y., Ishiguro Y.,
RA   Nishimura G., Matsuda H., Tsukuda M.;
RT   "Corrigendum: Antitumor effects of ZD6474 on head and neck squamous
RT   cell carcinoma.";
RL   Oncol. Rep. 35:2495-2495(2016).